Monday, September 29, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Lanxess Stock: Drastic Cuts Amid Market Turmoil

Robert Sasse by Robert Sasse
August 14, 2025
in Stocks
0
Lanxess Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Lanxess, the Cologne-based specialty chemicals firm, has slashed its 2025 earnings forecast due to worsening economic conditions, now projecting an operating profit of €520–580 million, down from €600–650 million. The company cited persistent U.S. tariff disputes and broader market uncertainty as key pressures. Cost-cutting measures include early closures of facilities in Krefeld-Uerdingen (60 jobs lost) and Widnes, UK (70 jobs affected), with expected annual savings of €50 million by late 2027. Q2 results underscored the challenges: revenue fell 13% to €1.47 billion, with agrochemicals and construction sectors hit hardest. Operating profit dropped 17% to €150 million, while net losses widened to €45 million.

Investor Confidence Erodes

The bleak outlook sparked a 3% stock decline to €23.60, extending a 20% slide since May. Analysts noted the forecast cut was steeper than anticipated, with one firm maintaining an "underperform" rating and a €21 target. Management warned of no near-term recovery, compounded by supply chain disruptions costing an additional €10 million. Lanxess joins a growing list of chemical firms downgrading expectations amid global economic headwinds.

Ad

Lanxess Stock: Buy or Sell?! New Lanxess Analysis from September 29 delivers the answer:

The latest Lanxess figures speak for themselves: Urgent action needed for Lanxess investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 29.

Lanxess: Buy or sell? Read more here...

Tags: Lanxess
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Royal Gold Stock
Stocks

Royal Gold Shares Surge to Record High on Acquisition Momentum

September 29, 2025
Unitedhealth Stock
Stocks

UnitedHealth Shares Present Conflicting Outlook for Investors

September 29, 2025
ASML Stock
Stocks

ASML Forges Strategic AI Alliance to Bolster Semiconductor Dominance

September 29, 2025
Next Post
Lenovo Stock

Lenovo Stock: Record Profits, Sharp Decline

JDC Stock

JDC Stock: Stellar Growth Defies Market Challenges

Bilfinger Stock

Bilfinger Stock: Strong Growth Amid Investor Caution

Recommended

Revolution Medicines Stock

Biotech’s Bold Bet: Revolution Medicines Secures Billions Despite Mounting Losses

4 weeks ago
Finance_Business (1)

Analyst Maintains Outperform Rating on WaFd Lowers Price Target

2 years ago
CareCloud Stock

CareCloud Achieves Profit Milestone Amid Market Skepticism

4 weeks ago
Technology Data analytics Stock Bull Market

Rockwell Automation Announces Dividend Distribution and Yield Comparison

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Fiserv’s Strategic Crossroads: Core Banking Strength Meets Legal Headwinds

IBM’s Quantum Leap: Financial Sector Breakthrough Signals New Growth Era

Xiaomi’s Strategic Crossroads: Smartphone Turbulence Meets Electric Ambition

Royal Gold Shares Surge to Record High on Acquisition Momentum

UnitedHealth Shares Present Conflicting Outlook for Investors

ASML Forges Strategic AI Alliance to Bolster Semiconductor Dominance

Trending

aTyr Pharma Stock
Analysis

aTyr Pharma Shares Continue Downward Trajectory Amid Technical Pressure

by Felix Baarz
September 29, 2025
0

aTyr Pharma's stock faced another challenging session on Friday, declining nearly 6% to close at $0.841 per...

BioNTech Stock

Can BioNTech Reinvent Itself Beyond the Pandemic?

September 29, 2025
Amazon Stock

Is Amazon the Most Undervalued Tech Titan?

September 29, 2025
Fiserv Stock

Fiserv’s Strategic Crossroads: Core Banking Strength Meets Legal Headwinds

September 29, 2025
IBM Stock

IBM’s Quantum Leap: Financial Sector Breakthrough Signals New Growth Era

September 29, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • aTyr Pharma Shares Continue Downward Trajectory Amid Technical Pressure
  • Can BioNTech Reinvent Itself Beyond the Pandemic?
  • Is Amazon the Most Undervalued Tech Titan?

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com